Turbu+ Australia

Turbu+ is a programme intended to assist people with asthma and/or COPD.

You are only able to participate in the Turbu+ programme if enrolled by your Healthcare Professional.

Turbu+ is a programme intended to assist people with asthma and/or COPD in recording and monitoring the actuations of prescribed inhaler usage. Users will interact with the programme through a mobile app. This mobile app receives, stores, and displays inhalation/usage events from remote sensors in the compatible Bluetooth-enabled monitoring (Turbu+) device attached to the user’s inhaler, to support them in adhering to their prescribed treatment regime. The app also provides users with pre-configured medication reminders and motivational messages encouraging adherence with their prescribed medication.

The Turbu+ programme is not intended to:

• Diagnose, determine, modify or adapt the healthcare professional's treatment decisions

• Monitor, in real time, the user's medication use

• Determine or change the user's medication or treatment plan or to recommend such changes

• Alter or analyse inhaler usage information, other than by formatting the data for display.

Turbu+ is a patient support programme which has been designed, developed & fully sponsored by AstraZeneca UK Ltd. AstraZeneca UK Ltd is the manufacturer of the Turbu+ app whose registered address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. United Kingdom.

The Turbu+ device has been designed and developed by Adherium Europe Ltd.

Approval ID:AU-2059/Prep Mar 2017/Next Update Due Mar 2018